Personalizing biomarker strategies in heart failure with galectin-3

Future Cardiology

Volumn 8, Issue 6, 2012, Pages 885-894

  Sherwi, Nasser ^a   Merali, Shermin ^a   Wong, Kenneth ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

galectin 3; heart failure; management; myocardial fibrosis; prognosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; GALECTIN 3; GELATINASE A; N ACETYL SERYL ASPARTYL LYSYL PROLINE; PECTIN; PROCOLLAGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; APOPTOSIS; AREA UNDER THE CURVE; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CELL ACTIVATION; CELL PROLIFERATION; CHEMOTAXIS; DIABETES MELLITUS; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; GENE OVEREXPRESSION; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART MUSCLE FIBROSIS; HUMAN; MACROPHAGE; MAST CELL; META ANALYSIS; MULTICENTER STUDY; MYOFIBROBLAST; NONHUMAN; OXYGEN CONSUMPTION; PHAGOCYTOSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY; SODIUM RETENTION; SYSTEMATIC REVIEW; TERMINAL CARE; WATER RETENTION;

BIOLOGICAL MARKERS; FIBROSIS; GALECTIN 3; HEART FAILURE; HUMANS; OLIGOPEPTIDES; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH; VENTRICULAR REMODELING;

EID: 84870192207     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.65     Document Type: Review

References (48)

1. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539-1549 (2005). (Pubitemid 40517094)
2. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269(33), 20807-20810 (1994).
3. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol. Int. 31(7), 655-662 (2007). (Pubitemid 46765120)
4. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl Acad. Sci. 103(13), 5060-5065 (2006).
5. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172(2), 288-298 (2008). (Pubitemid 351282017)
6. Nishi Y, Sano H, Kawashima T et al. Role of galectin-3 in human pulmonary fibrosis. Allergol. Int. 56(1), 57-65 (2007). (Pubitemid 46449664)
7. Sharma UC, Pokharel S, Van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19), 3121-3128 (2004) • This important preclinical experiment demonstrated how galectin-3 causes myocardial fibrosis and heart failure. (Pubitemid 39492008)
8. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am. J. Pathol. 172(1), 247-255 (2008). (Pubitemid 351186385)
9. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am. J. Pathol. 152(5), 1199-1208 (1998). (Pubitemid 28221873)
10. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int. J. Cancer 81(4), 519-526 (1999). (Pubitemid 29203046)
11. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J. Pathol. 187(4), 481-489 (1999). (Pubitemid 29118282)
12. Liu YH, D'Ambrosio M, Liao TD et al. N-acetyl-seryl-aspartyl-lysyl- proline prevents cardiac remodeling and dysfunction induced by Galectin-3, a mammalian adhesion/growth-regulatory lectin. Am. J. Physiol. Heart Circ. Physiol. 296(2), H404-H412 (2009) •• Galectin-3 caused myocardial fibrosis, and importantly, an agent which inhibits galectin-3 neutralizes myocardial fibrosis.
13. Sharma U, Rahleb NE, Pokharel S et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertensioninduced target organ damage. Am. J. Physiol. Heart Circ. Physiol. 294, H1226-H1232 (2008). (Pubitemid 351468718)
14. Lin Y, Lin L, Wu Y et al. The relationship between serum Galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clinica Chimica Acta 409, 96-99 (2009) • In patients with heart failure, there is a correlation between raised levels of galectin-3 and procollagen III N-terminal peptide, another marker of myocardial fibrosis.
15. Lopez-Andrès N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur. J. Heart Fail. 14(1), 74-81 (2012).
16. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of Galectin. Glycoconj. J. 19(7-9), 527-535 (2004).
17. Rabinovich GA, Baum LG, Tinari N et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23(6), 313-320 (2002). (Pubitemid 34628775)
18. Rubinstein N, Ilarregui JM, Toscano MA, Rabinovich GA. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 64(1), 1-12 (2004). (Pubitemid 38850363)
19. Eis V, Luckow B, Vielhauer V et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J. Am. Soc. Nephrol. 15(2), 337-347 (2004). (Pubitemid 38140774)
20. Reifenberg K, Lehr HA, Torzewski M et al. Interferon-g induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am. J. Pathol. 171(2), 463-472 (2007). (Pubitemid 47344679)
21. Frangogiannis NG. The immune system and cardiac repair. Pharmacol. Res. 58(2), 88-111 (2008).
22. Nachtigal M, Legrand A, Nagpal ML, Nachtigal SA, Greenspan P. Transformation of rabbit vascular smooth muscle cells by transfection with the early region of SV40 DNA. Am. J. Pathol. 136(2), 297-306 (1990). (Pubitemid 20074605)
23. Arar C, Gaudin JC, Capron L, Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett. 430(3), 307-311 (1998). (Pubitemid 28337934)
24. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem. Biophys. Res. Commun. 280(4), 1183-1185 (2001).
25. Vlassara H, Li YM, Imani F et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol. Med. 1(6), 634-646 (1995).
26. Nakamura Y, Horii Y, Nishino T et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6), 1649-1656 (1993). (Pubitemid 24058268)
27. Van Kimmenade RR, Januzzi JL, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48(6), 1217-1224 (2006) •• In 599 patients with acute dyspnea, galectin-3 is 80% sensitive at diagnosing heart failure and 75% sensitive at predicting 60-day mortality. (Pubitemid 44345127)
28. Maisel A, Mueller C, Adams K et al. State of the art: using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 10(9), 824-839 (2008).
29. Milting H, Ellinghaus P, Seewald M et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J. Heart Lung. Transplant. 27(6), 589-596 (2008). (Pubitemid 351715387)
30. Lok DJ, Van Der Meer P, De La Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol. 99(5), 323-328 (2010) • In 232 patients with heart failure, a galectin-3 value of 17.72 provided the best sensitivity and specificity for identifying patients who died.
31. Sanchez F. Galectin-3-independent prognosis in heart failure. Clin. Res. Cardiol. 100, 183 (2011).
32. Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL. Integrating plasma high-sensitiviy C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest. Heart Fail. 17, 105-109 (2011).
33. Hogenhuis J, Voors AA, Jaarsma T, Hilege HL, Hoes AW, Van Veldhuisen DJ. Low prevalence of B-type natriuretic peptide levels >100 pg/ml in patients with heart failure at hospital discharge. Am. Heart J. 151, 1012. e1-5 (2006).
34. De Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma Galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43, 60-68 (2011) •• Galectin-3 has prognostic potential, however, its use for monitoring disease progression or treatment response is limited because levels are stable in different loading conditions.
35. De Boer RA, Voors AA, Muntendam P, Van Gilst WH, Van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 11(9), 811-817 (2009).
36. Calvier L, Martin-Fernãndez B, Lahera V et al. Galectin-3 is a potential mediator of aldosterone effects in vascular remodelling. Artery Res. 5(4), 165 (2011).
37. Bichara M, Attmane-Elakeb A, Brown D et al. Exploring the role of Galectin 3 in kidney function: a genetic approach. Glycobiology 16(1), 36-45 (2006). (Pubitemid 43009806)
38. Zannad F, Rossignol P, Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart Fail. Rev. 15, 319-329 (2010).
39. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102, 2700-2706 (2000).
40. Izawa H, Murohara T, Nagata K et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112, 2940-2945 (2005). (Pubitemid 41612295)
41. Shah R, Chen-Tournoux A, Picard M et al. Galectin-3, cardiac structure and function, and long-tem mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail. 12, 826-832 (2010).
42. Ueland T, Aukrust P, Broch K et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int. J. Cardiol. 150(3), 361-364 (2011).
43. Gullestad L, Ueland T, Kjekshus T et al. Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (CORONA). Eur. Heart J. 33(18), 2290-2296 (2012).
44. McCullough PA, Olabatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev. Cardiovasc. Med. 12(4), 200-210 (2011).
45. Henderson NC, Sethi T. The regulation of inflammation by Galectin-3. Immunol. Rev. 230(1), 160-171 (2009).
46. Weigert J, Neumeier M, Wanninger J et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J. Clin. Endocrinol. Metab. 95(3), 1404-1411 (2010).
47. Friedrichs J, Torkko J, Helenius J et al. Contributions of galectin-3 and -9 to epithelial cell adhesion analyzed by single cell force spectroscopy. J. Biological. Chem. 282(40), 29375-29383 (2007). (Pubitemid 350043353)
48. Ho JE, Liu C, Lyass A et al. Galectin-3, a marker of cardiac fibrosis, predicts incident Heart Failure in the Community. JACC 60(14), 1249-56 (2012).